GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (LTS:0W4N) » Definitions » Additional Paid-In Capital

Formycon AG (LTS:0W4N) Additional Paid-In Capital : €496.02 Mil(As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Formycon AG Additional Paid-In Capital?


Formycon AG's quarterly additional paid-in capital increased from Dec. 2023 (€412.87 Mil) to Jun. 2024 (€494.91 Mil) and increased from Jun. 2024 (€494.91 Mil) to Dec. 2024 (€496.02 Mil).

Formycon AG's annual additional paid-in capital increased from Dec. 2022 (€343.42 Mil) to Dec. 2023 (€412.87 Mil) and increased from Dec. 2023 (€412.87 Mil) to Dec. 2024 (€496.02 Mil).

Formycon AG Additional Paid-In Capital Historical Data

The historical data trend for Formycon AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Additional Paid-In Capital Chart

Formycon AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.99 82.79 343.42 412.87 496.02

Formycon AG Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 343.42 411.54 412.87 494.91 496.02

Formycon AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Formycon AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Formycon AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (LTS:0W4N) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:HPHA STU:T9G FRA:OMY XTER:MDG1 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269
Traded in Other Exchanges
FYB:Germany
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Website
https://www.formycon.com
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Formycon AG Headlines

No Headlines